This protocol addresses postmenopausal women with solid papillary carcinoma of the breast with evidence of invasion where the tumour tests positive for oestrogen receptors. Both menopausal status and receptor status are central to determining the appropriate adjuvant systemic approach.
Postmenopausal status combined with oestrogen receptor-positive breast cancer. The patient's individual risk level further refines which adjuvant hormonal agent is most appropriate.
Adjuvant hormonal therapy forms the basis of this protocol. The primary agent belongs to a specific class of endocrine therapy, with a distinct alternative reserved for patients at lower risk or when the first-line option cannot be used — the full selection criteria, sequencing, and duration are available in the complete regimen.